Aflatoxin M1 Reduction by Probiotic Strains in Iranian Feta Cheese
نویسندگان
1 Bel Rouzaneh Dairy Product Company, Qazvin, I.R. IRAN
2 Department of Food Science and Technology, National Nutrition and Food Technology Research Institute, Faculty of Nutrition Sciences, Food Science and Technology, Shahid Beheshti University of Medical Sciences, I.R. IRAN
3 Department of Food Science and Technology, National Nutrition and Food Technology Research Institute, Faculty of Nutrition Sciences, Food Science and Technology, Shahid Beheshti University of Medical Sciences, Iran
4 Department of Food Science and Technology, School of Nutritional Sciences and Food Technology, Kermanshah University of Medical Sciences, Kermanshah, I.R. IRAN
5 Department of Food Science and Technology, Faculty of Agriculture, Ferdowsi University of Mashhad, Mashhad, I.R. IRAN
6 Students Research Committee, Department of Food Science and Technology, National Nutrition and Food Technology Research Institute, Faculty of Nutrition Sciences, Food Science and Technology, Shahid Beheshti University of Medical Sciences, I.R. IRAN
7 Department of Food Science and Technology, School of Nutritional Sciences and Food Technology, Kermanshah University of Medical Sciences, Kermanshah, I.R. IRAN
doi
10.30492/ijcce.2020.43471چکیده
Among the fermented products, cheese has a good potential to deliver probiotic microorganisms into the gastrointestinal system due to its high protein and fat contents. The contamination of milk with aflatoxin M deserves attention concerning cheese consumption due to the harmful effects on human health. The present research studied the reduction of aflatoxin M1 (AFM1) by two well-known probiotic strains in artificially aflatoxin-contaminated Feta cheese. Changes in pH, the viability of the probiotic strains, and the level of aflatoxin in the samples were analyzed during 60-day storage. The results showed that all samples containing probiotics dramatically reduced the AFM1 levels. From both the health and economic aspects, the B. bifidum species at an inoculation level of 107 CFU/mL has proven to be the best treatment, due to the lowest cost of probiotics, highest survival rate, and 30.12% reduction of AFM1.
